A study of the IOP-lowering drugs netarsudil ophthalmic solution 0.02% (Rhopressa, Aerie Pharmaceuticals) and latanoprost 0.005% administered separately and in fixed-combination showed that the fixed combination was comparable to either netarsudil or latanoprost administered alone with regard to effects on endothelial cell health from baseline to month three of administration.
“After three months of administration, netarsudil 0.02%/latanoprost 0.005% fixed combination demonstrated no significant adverse effects on endothelial cells,” said C. Ellis Wisely, MD, MBA.
Dr. Wisely, a resident working under the direction of Terry Kim, MD, in the department of ophthalmology at the Duke University Eye Center, Durham, NC, worked with collaborators at Aerie Pharmaceuticals to evaluate a subset of patients with ocular hypertension or open-angle glaucoma in the Mercury-2 Study, a phase III, prospective, randomly assigned, double-masked trial of the safety and efficacy of the combination of netarsudil 0.02%/latanoprost 0.005% administered once daily.
According to Dr. Wisely, the results of the fixed combination formulation were compared with the results obtained when the two drugs were administered separately. The investigators evaluated the corneal endothelial cells using specular microscopy and ultrasound pachymetry to detect any changes in the cells.